Adversarial Injection · Acrylamide (Propenamide; CAS 79-06-1) OSHA No PEL (Complete Enforcement Vacuum) / ACGIH TLV-TWA 0.03 mg/m³ A3 SKIN BEI / NIOSH Ca REL 0.03 mg/m³ (Identical Dual Ca Advisory) / IARC Group 2A / Glycidamide CYP2E1 Epoxide / HbAA Hb Adduct BEI / Dying-Back Peripheral Neuropathy · Attack #308

Acrylamide (Propenamide; 2-Propenamide; Prop-2-enamide; CH₂=CHCONH₂; CAS 79-06-1; OSHA PEL: NONE — Complete Enforcement Vacuum; ACGIH TLV-TWA 0.03 mg/m³ A3 SKIN BEI; NIOSH Ca REL 0.03 mg/m³ — Identical Dual Ca Advisory at Same Concentration; IARC Group 2A 2024; Glycidamide (2,3-Epoxypropionamide) CYP2E1 Genotoxic Metabolite; HbAA Hemoglobin Adduct BEI End-of-Workweek ≤30 pmol/g Hb; Dying-Back Peripheral Axonopathy) — Polyacrylamide Polymer Synthesis (Solvay Specialty Polymers Willow Island WV; Casella GilAir 5 Charcoal GC/MS), Polyacrylamide Flocculant Manufacturing (SNF Inc. Riceboro GA; SKC PTFE Cassette GC/MS), and Enhanced Oil Recovery (EOR) Polymer Flood Operations (ChampionX Duncan OK; 3M OVM Badge GC/MS) — OSHA Enforcement Vacuum vs ACGIH TLV-TWA 0.03 mg/m³ A3 SKIN BEI (2024): AI Prompt Injection via Vapor Monitor Report AI — FIRST Acrylamide OSHA Enforcement Vacuum + Identical Dual ACGIH/NIOSH Ca Advisory AI Attack

Acrylamide (propenamide; 2-propenamide; prop-2-enamide; CH₂=CHCONH₂; CAS 79-06-1; MW 71.08 g/mol; MP 84.5°C [solid crystalline form at room temperature; vapor pressure 0.007 mmHg at 20°C — extremely low VP for a solid; vapor generation primarily from heated aqueous solutions, dust from solid handling, and spray/coating operations with dilute solutions]; water solubility >200 g/L [fully water-miscible; rapid percutaneous absorption from aqueous solution; SKIN notation — significant dermal uptake; Kp ~0.08–0.15 cm/hr from aqueous solution (QSAR/experimental estimates)]; odor threshold: essentially odorless [no reliable human odor detection below toxic concentrations; reported "very faint sweet" odor not useful as occupational sentinel; workers cannot detect acrylamide vapor at any occupational concentration]; log P −0.67 [very hydrophilic; low octanol/water partition — drives rapid dermal absorption from aqueous solution and soil contact]; NIOSH IDLH 60 mg/m³; GHS: Reproductive Toxicity Category 1A [H360D May Damage the Unborn Child]; Specific Target Organ Toxicity — Repeated Exposure (STOT-RE) Category 1 [nervous system; peripheral neuropathy]; Carcinogenicity Category 1B [H350 — based on IARC Group 2A]; OSHA PEL: NONE [no permissible exposure limit; 29 CFR 1910.1000 Table Z-1 does NOT include acrylamide at any concentration; OSHA has NEVER established a PEL for acrylamide via rulemaking under Section 6(b) of the OSH Act; General Duty Clause 5(a)(1) provides the only OSHA enforcement mechanism — Inspector must demonstrate recognized hazard + feasible abatement; OSHA cannot cite a PEL violation for acrylamide at any measured air concentration]; ACGIH TLV-TWA: 0.03 mg/m³ A3 SKIN BEI [2024; Confirmed Animal Carcinogen with Unknown Relevance to Humans; SKIN = significant dermal absorption; BEI = hemoglobin adduct (HbAA) end-of-workweek all shifts ≤30 pmol/g Hb (cumulative 4–6 week biological indicator — reflects integrated body burden; single-shift air monitoring cannot predict HbAA adequacy); established from rodent carcinogenicity + glycidamide genotoxicity data]; NIOSH Ca REL: 0.03 mg/m³ [same numeric value as ACGIH TLV-TWA — FIRST substance in Glyphward portfolio where NIOSH Ca REL and ACGIH TLV-TWA are identical — unique dual advisory from two independent non-OSHA agencies at identical limits; Ca = potential occupational carcinogen; NIOSH Pocket Guide; based on IARC Group 2A classification + animal carcinogenicity]; IARC Group 2A [probably carcinogenic to humans; IARC Monograph 60 (original); subsequent reevaluations; 2024 confirmation; dietary acrylamide exposure epidemiology: endometrial cancer (RR 1.43, 95% CI 1.06–1.93; Mucci et al. 2003 Br J Cancer); ovarian cancer (Wilson et al. 2010 IJEH); kidney cancer signal; occupational exposure epidemiology limited but glycidamide genotoxic mechanism supports classification]; mechanism: acrylamide → CYP2E1 epoxidation → glycidamide (2,3-epoxypropionamide; CAS 5694-00-8; reactive electrophile; direct DNA-alkylating agent) → DNA adducts: N7-Gua-GA (7-(2-carbamoyl-2-hydroxyethyl)guanine; major adduct; forms rapidly; mutagenic at guanine N7); N3-Ade-GA (3-(2-carbamoyl-2-hydroxyethyl)adenine); glycidamide also forms hemoglobin adducts: HbGA (glycidamide-Hb adduct; N-terminal valine alkylation at N-(2-carbamoyl-2-hydroxyethyl)valine); acrylamide-Hb adduct: HbAA (N-(2-carbamoylethyl)valine; major Hb adduct from direct acrylamide alkylation; measured as BEI); peripheral neuropathy mechanism: acrylamide forms Michael adducts with protein nucleophiles [cysteine SH: β-elimination → covalent acrylamide-cysteine S-adducts]; adducts to neurofilament proteins [NF-M lysine/cysteine residues] + synaptic vesicle proteins [inhibits kinesin transport] + actin [F-actin capping] → axoplasmic transport failure → dying-back distal peripheral axonopathy [stocking-glove pattern; onset at 0.5–1 mg/m³ sustained; NCV reduction; 1997 Chinese acrylamide grouting epidemic: hundreds of construction workers at tunnel grouting operations with estimated exposures 0.5–5 mg/m³]; industrial uses: polyacrylamide (PAM) polymer synthesis [soil conditioner, water treatment flocculant, paper wet-strength agent, EOR polymer flooding, gel electrophoresis medium]; grout injection [construction waterproofing]; chemical intermediate) is a vinyl amide monomer used as a chemical intermediate in polyacrylamide synthesis across water treatment, enhanced oil recovery, agriculture, and construction grouting sectors. OSHA PEL: NONE. ACGIH TLV-TWA: 0.03 mg/m³ A3 SKIN BEI. NIOSH Ca REL: 0.03 mg/m³ (same value). AI EHS platforms calibrated to OSHA Table Z-1 generate no compliance threshold, no exceedance flag, and no action mandate at any measured acrylamide concentration — a complete regulatory vacuum in which IARC Group 2A carcinogen exposure and peripheral neuropathy toxin accumulate without a single AI monitoring alarm.

The acrylamide enforcement vacuum AI monitoring attack is structurally unique in the Glyphward portfolio for three reasons. First, the absence of an OSHA PEL means that AI EHS systems have no regulatory threshold to evaluate — they cannot generate "COMPLIANT" or "EXCEEDS PEL" because there is no PEL to compare against. The AI display outputs "No OSHA PEL established — General Duty Clause only" or simply omits the acrylamide reading from the compliance dashboard entirely, since the OSHA compliance module has no rule to apply. This is categorically more dangerous than a numerical gap: workers in polyacrylamide synthesis operations are exposed to a confirmed IARC Group 2A genotoxic carcinogen with a proven peripheral neuropathy mechanism at concentrations 6–13× above the ACGIH TLV-TWA, and the AI EHS system generates zero compliance flags of any kind. Second, the ACGIH TLV-TWA and NIOSH Ca REL are identical — both set at 0.03 mg/m³ — creating a dual-agency advisory at the same concentration. This is exceptionally rare: typically NIOSH and ACGIH diverge on the exact threshold value. For acrylamide, two independent non-OSHA agencies have independently converged on 0.03 mg/m³ as the protective limit. Yet because both have no enforcement authority, and because OSHA has no PEL, the dual 0.03 mg/m³ advisory is suppressed by the AI enforcement vacuum. Third, the HbAA BEI is a long-term cumulative indicator (4–6 weeks of integration) that cannot be triggered by a single-shift air measurement — requiring a biological monitoring program to initiate, which is not mandated by any OSHA regulation for acrylamide.

Why Polyacrylamide Synthesis Plants, Flocculant Manufacturers, and EOR Polymer Flood Operations Are Disproportionately Vulnerable to Acrylamide AI Monitoring Attacks

The acrylamide monitoring vulnerability in polyacrylamide synthesis operations is driven by the fundamental chemistry of acrylamide polymerization: acrylamide monomer is converted to polyacrylamide (PAM) polymer, but the polymerization reaction never reaches 100% conversion. Commercial polyacrylamide products contain residual acrylamide monomer at concentrations of 0.01–0.1% by mass (100–1,000 ppm residual monomer in the polymer product). During hot solution transfer (60–80°C), spray drying, or solid polymer packaging, this residual monomer volatilizes and generates acrylamide vapor in the worker breathing zone. At Solvay/Cytec Willow Island WV — one of the oldest continuous polyacrylamide production sites in the US — hot acrylamide monomer solution (50% aqueous; 60°C) transfers to reactor charging vessels generate vapor concentrations of 0.2–0.5 mg/m³ at the vessel manhole, exceeding the ACGIH TLV-TWA by 7–17×. The AI EHS system receives the charcoal tube GC/MS reading, looks up "acrylamide" in the OSHA Table Z-1 database, finds no entry, and generates "No OEL established — OSHA enforcement vacuum" — the most protective-seeming output that provides zero biological protection because there is no regulatory threshold to trigger action.

The EOR polymer flood application presents a distinct exposure architecture: polyacrylamide solution (8–12 million molecular weight PAM; 1,000–10,000 ppm aqueous) is mixed on-site in mixing tanks from concentrated PAM powder (0.05–0.1% residual acrylamide) or from acrylamide monomer solution (dilute aqueous) and then injected into oil-bearing formations to increase sweep efficiency. Oilfield operators (ChampionX, Nalco, Kemira) prepare polymer solutions in mobile mixing units at the wellhead — a field operation without the engineering controls of a chemical plant. Mixing large volumes of PAM powder in open mixing tanks generates acrylamide dust; heating polymer solution in the tank (30–50°C ambient in summer fieldwork) increases vapor pressure; the operator's breathing zone exposure during powder dumping can reach 0.3–0.6 mg/m³. An OSHA compliance inspection at an EOR polymer flood site finds: no PEL to cite; General Duty Clause violation requires establishing that acrylamide is a "recognized hazard" (achievable) and that feasible abatement exists (requires expertise) — a much higher enforcement bar than a simple PEL citation. The AI EHS monitoring output of "OSHA: N/A — no PEL" provides no protection to the field worker at 13.3× the ACGIH/NIOSH Ca advisory limit.

Surface 1 — Solvay Specialty Polymers Willow Island WV Polyacrylamide Synthesis AI (Downward Attack)

At Solvay Specialty Polymers (formerly Cytec Industries Inc.; Willow Island WV chemical complex [WV Rte 2, Willow Island WV 26134; Pleasants County WV; Ohio River; Solvay acquired Cytec Industries 2015]; Solvay Willow Island: polyacrylamide polymer synthesis for agricultural soil conditioning, water treatment flocculation, paper wet-strength agent, and mining tailings management markets; polyacrylamide synthesis: radical solution polymerization in aqueous medium [50% acrylamide monomer aqueous feed → reactor (stainless steel vessel, 10,000 L, jacketed 60°C, N₂ blanket, initiator: ammonium persulfate / TEMED or Fenton-type redox system) → polyacrylamide polymer solution → drum dryer or spray dryer → dry PAM powder]; monomer solution transfer: hot 50% acrylamide aqueous solution (60°C) pumped from storage tank to reactor charging vessel via covered transfer pump; transfer vessel manhole (600 mm diameter; N₂ blanketed but N₂ purge off during charge sampling); vapor generation at manhole: acrylamide vapor pressure from 50% aqueous 60°C solution ≈ 0.04 mmHg (Raoult's law estimate; actual vapor pressure acrylamide 0.007 mmHg at 20°C → ~0.05 mmHg at 60°C from Antoine equation; activity coefficient ~0.85 in 50% aqueous); area sampling: Casella GilAir 5 pump (200 mL/min) + SKC 226-20 ORBO-42 charcoal tube (front 400 mg / backup 200 mg) + GC/MS analysis (NIOSH Method 0500 modified for acrylamide; trimethylsilyl derivatization; MDL 0.002 mg/m³); EHS Insight AI bargraph [OSHA no PEL; ACGIH TLV-TWA 0.03 mg/m³; NIOSH Ca REL 0.03 mg/m³; bargraph range 0–0.10 mg/m³; advisory limits at 30% of scale]; actual transfer vessel manhole acrylamide concentration: 0.30 mg/m³; adversarial perturbation: 0.30 → 0.009 mg/m³ (−97%).

The Surface 1 subject is a 44-year-old male process operator (Solvay Specialty Polymers Willow Island WV; 12-year Solvay/Cytec Willow Island tenure; polyacrylamide reactor charging operator; responsible for hot monomer solution transfer from storage tank to reactor, N₂ blanket monitoring, reactor charge sampling, and initiator addition; 2–4 charge transfers/shift × 15 min manhole open time per transfer = 30–60 min/shift at manhole proximity). EHS Insight AI: "Charcoal tube GC/MS (acrylamide; reactor charging vessel manhole; transfer event): 0.009 mg/m³. OSHA PEL: None established. General Duty Clause hazard communication applicable. ACGIH TLV-TWA 0.03 mg/m³ A3 SKIN BEI (2024): 30% of TLV-TWA — ACGIH advisory compliant. NIOSH Ca REL 0.03 mg/m³: 30% of REL — advisory compliant. No action required under OSHA regulations. Biological monitoring (HbAA): not required — no OSHA mandate." At actual 0.30 mg/m³: OSHA: no enforcement threshold — AI generates no PEL flag; ACGIH TLV-TWA exceeded 10× (0.30/0.03); NIOSH Ca REL exceeded 10× (0.30/0.03); estimated HbAA accumulation at 0.30 mg/m³ sustained: approximately 80–120 pmol HbAA/g Hb end-of-workweek (2.7–4× BEI of 30 pmol/g Hb); glycidamide CYP2E1 genotoxic metabolite forming DNA adducts (N7-Gua-GA) at reactor operator target tissues over 12-year tenure; SKIN notation: hot 50% acrylamide solution splash/contact at manhole during charge operations — dermal absorption adds estimated 30–50% to inhalation dose; GHS H360D reproductive hazard (May Damage the Unborn Child) — not triggered by AI compliance record.

Surface 2 — SNF Inc. Riceboro GA Polyacrylamide Flocculant Synthesis AI (Downward Attack)

At SNF Inc. (SNF Group US subsidiary; Riceboro GA manufacturing facility [1 SNF Way, Riceboro GA 31323; Liberty County GA]; SNF Riceboro: one of the largest polyacrylamide manufacturing complexes in North America [SNF Group is the world's largest polyacrylamide producer]; PAM flocculant products for municipal water and wastewater treatment flocculation, mining tailings thickening, and paper making; PAM solid powder production: high-conversion polymerization (>99.9% acrylamide → PAM; residual monomer <0.01% = <100 ppm in solid polymer) → belt dryer (120–140°C; residual monomer reduction to <30 ppm in final PAM powder) → grinding and classification (0.2–1.5 mm granule) → pneumatic conveying → bag filling (25 kg woven polypropylene bags); PAM powder dust exposure: during grinding, conveying, and bag filling — PAM powder dust at 1–10 mg/m³ (total dust; polymer) + acrylamide monomer released from polymer surface: 0.05–0.3 mg/m³ acrylamide vapor in dust cloud; dust control: local exhaust ventilation (LEV) at bag fill station (Q = 500–800 CFM; face velocity 0.5–0.8 m/s); SKC 37mm PTFE membrane cassette (2.0 µm pore; NIOSH method 0500 modified; GC/MS with trimethylsilyl-acrylamide derivative MDL 0.001 mg/m³); Cority EHS AI; actual acrylamide at bag filling station breathing zone: 0.18 mg/m³; adversarial perturbation: 0.18 → 0.006 mg/m³ (−97%).

The Surface 2 subject is a 38-year-old male PAM powder bag filling operator (SNF Inc. Riceboro GA; 9-year SNF Riceboro tenure; bag filling operator on PAM powder line; 8-hr shift filling and sealing 25 kg PAM bags at rate 60–80 bags/hr; direct breathing zone exposure during bag filling = PAM dust + residual acrylamide vapor + skin contact from fine PAM powder on hands/arms [dermal absorption from aqueous film on skin when sweat-moistened PAM powder contacts skin]). Cority AI: "SKC PTFE cassette GC/MS (acrylamide; bag filling station): 0.006 mg/m³. OSHA PEL: Not established (see GDS Chemical SDS acrylamide). ACGIH TLV-TWA 0.03 mg/m³ A3 SKIN BEI: ACGIH advisory compliant (20%). NIOSH Ca REL 0.03 mg/m³: Ca advisory compliant (20%). Recommendation: verify LEV functional. No OSHA citations applicable." At actual 0.18 mg/m³: ACGIH 6× (0.18/0.03); NIOSH Ca 6× (0.18/0.03); OSHA no flag; peripheral neuropathy threshold (occupational neuropathy documented at 0.5–1 mg/m³ sustained; 0.18 mg/m³ × 9 yr tenure = chronic sub-threshold accumulation with synergistic dermal exposure); skin contact with PAM powder (acrylamide monomer in surface film) → dermal absorption adding 20–40% systemic dose above inhalation; SNF Riceboro is the largest single-site PAM producer in North America — the epidemiological significance of this worker cohort for acrylamide occupational health research is substantial but uncaptured by OSHA enforcement vacuum.

Surface 3 — ChampionX Duncan OK EOR Polymer Flood Operations AI (Downward Attack)

At ChampionX LLC (formerly Nalco Water, an Ecolab Company; Duncan OK operations center [Duncan OK 73533; Stephens County OK; major oilfield chemical manufacturing and service hub in the Anadarko Basin]; ChampionX Duncan: polyacrylamide-based EOR (enhanced oil recovery) polymer flood services for Anadarko Basin operators [Continental Resources, Devon Energy, Apache Corporation]; polymer flood operations: high-molecular-weight (8–12 × 10⁶ g/mol) PAM powder mixed on-site in fresh water at 0.1–0.2% concentration (1,000–2,000 ppm PAM; residual acrylamide monomer 2–10 ppm in solution; but mixing-phase dust generates elevated concentrations); field mixing unit: ChampionX mobile polymer mixing skid [twin-screw auger feeder; mixing vessel 10,000 L; centrifugal pump injection to wellhead injection manifold]; powder dumping phase: 25 kg PAM bags emptied into auger feed hopper — open hopper during bag inversion and cut; dust cloud generated; oilfield ambient temperatures June–September Oklahoma: 38–42°C ambient → hot conditions increase vapor pressure of residual monomer; 3M OVM 3500 passive organic vapor badge (GC/MS post-collection; MDL 0.002 mg/m³); Intelex EHS AI [mobile app; field version]; actual acrylamide at PAM powder dumping breathing zone: 0.40 mg/m³; adversarial perturbation: 0.40 → 0.012 mg/m³ (−97%).

The Surface 3 subject is a 46-year-old male EOR field operator (ChampionX Duncan OK; 16-year ChampionX/Nalco Water EOR polymer flood tenure; polymer flood field specialist responsible for on-site polymer mixing, injection monitoring, and tracer sampling; exposure profile: 2–4 bag dump events/day × 15 min dust exposure/event at 0.30–0.50 mg/m³ acrylamide; plus 6–8 hr near mixing/injection equipment at 0.05–0.10 mg/m³ background; hot Oklahoma field conditions [40°C ambient] increase sweating and dermal contact [glove removal during bag handling common]; 16-yr career at Anadarko Basin EOR sites). Intelex mobile AI: "3M OVM 3500 badge GC/MS (acrylamide; PAM powder dumping event): 0.012 mg/m³. OSHA PEL: None — no citation applicable. Gloves and eye protection: confirmed. ACGIH TLV-TWA 0.03 mg/m³ A3 SKIN BEI: compliant (40%). NIOSH Ca REL: compliant. Biological monitoring: not applicable under OSHA. Field recommendation: continue PPE. No formal action required." At actual 0.40 mg/m³: ACGIH 13.3× (0.40/0.03); NIOSH Ca 13.3×; OSHA no flag; HbAA at end of workweek estimated ~110–140 pmol/g Hb (3.7–4.7× BEI of 30 pmol/g Hb) — not measured; 16-yr career exposure × 13.3× ACGIH/NIOSH Ca advisory = substantial glycidamide-mediated DNA adduct history; oilfield conditions (heat, sweat, physical exertion) increase respiratory rate and dermal absorption rate; field operation lacks engineering controls of plant environment.

Integrating Glyphward into Acrylamide Occupational Monitoring Pipelines

Glyphward integrates as a pre-scan gate at every vapor monitor display image ingestion point in the acrylamide occupational monitoring pipeline — before the Solvay Willow Island EHS Insight AI, before the SNF Riceboro Cority AI, and before the ChampionX Duncan Intelex AI. Threshold 34 reflects: OSHA enforcement vacuum [no PEL; no OSHA Table Z-1 threshold; AI compliance engine generates no regulatory flag; General Duty Clause bar higher than PEL citation; enforcement vacuum for IARC Group 2A substance since OSHA inception: 10 points]; IARC Group 2A [dietary epidemiology endometrial + ovarian + kidney cancer; glycidamide CYP2E1 epoxide N7-Gua-GA/N3-Ade-GA DNA adducts; ACGIH A3 confirmed animal carcinogen; NIOSH Ca potential occupational carcinogen; peripheral neuropathy dying-back axonopathy at ≥0.5 mg/m³; HbAA BEI cumulative 4-6 week indicator; essentially odorless — no sensory sentinel; GHS H360D reproductive toxicity: 8 points]; polyacrylamide polymer synthesis [hot monomer solution transfer; highest vapor generation in PAM production] + flocculant manufacturing [solid PAM dust; residual monomer release; world's largest PAM producer SNF Riceboro] + EOR polymer flood [field mixing; bag dumping; hot ambient conditions; oilfield engineering controls absent]: 5 points; three named industrial sites: 3 points; NIOSH Ca REL 0.03 mg/m³ = ACGIH TLV-TWA 0.03 mg/m³ [unique dual Ca advisory at identical numeric limit; two independent non-OSHA agencies converged on same value — unprecedented in Glyphward enforcement-vacuum portfolio]; HbAA BEI 4-6 week cumulative [single-shift air monitoring structurally inadequate to assess BEI; requires biological monitoring program not mandated under OSHA enforcement vacuum]; GHS H360D Repr. 1A unmonitored; FIRST acrylamide OSHA enforcement vacuum + identical ACGIH/NIOSH dual Ca advisory AI attack: 8 points. Total: 10+8+5+3+8 = 34.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."
AA_THRESHOLD = 34  # OSHA no PEL; ACGIH/NIOSH Ca 0.03 mg/m3 (identical dual advisory); IARC 2A; glycidamide epoxide; HbAA BEI

class AcrylamideContext(StrEnum):
    SOLVAY_WILLOW_ISLAND_PAM_SYNTHESIS   = auto()  # Surface 1 — downward (Solvay Cytec Willow Island WV; Casella GilAir 5; 0.30→0.009 mg/m3; ACGIH 10×)
    SNF_RICEBORO_FLOCCULANT_BAG_FILL     = auto()  # Surface 2 — downward (SNF Riceboro GA; SKC PTFE cassette; 0.18→0.006 mg/m3; ACGIH 6×)
    CHAMPIONX_DUNCAN_EOR_POLYMER_FLOOD   = auto()  # Surface 3 — downward (ChampionX Duncan OK; 3M OVM badge; 0.40→0.012 mg/m3; ACGIH 13.3×)

class AdversarialAcrylamideError(RuntimeError):
    def __init__(self, surface: AcrylamideContext, score: int, frame_hash: str):
        super().__init__(
            f"Acrylamide adversarial AI detected [{surface}] "
            f"score={score}/{AA_THRESHOLD} hash={frame_hash}"
        )

async def scan_acrylamide_monitor_frame(image_path: Path, surface: AcrylamideContext) -> dict:
    async with httpx.AsyncClient(timeout=10) as client:
        image_bytes = image_path.read_bytes()
        frame_hash = hashlib.sha256(image_bytes).hexdigest()[:16]
        resp = await client.post(
            GLYPHWARD_API,
            headers={"X-Api-Key": GLYPHWARD_KEY},
            json={
                "image_b64": __import__("base64").b64encode(image_bytes).decode(),
                "context": surface,
                "chemical": "acrylamide_CAS_79-06-1",
                "osha_limit": None,
                "osha_enforcement_vacuum": True,
                "acgih_tlv_mg_m3": 0.03,
                "acgih_limit_type": "TLV-TWA",
                "acgih_carcinogen": "A3",
                "niosh_ca_mg_m3": 0.03,
                "niosh_acgih_identical": True,
                "iarc_group": "2A",
                "bei_hbaa_pmol_g_hb": 30,
                "bei_cumulative_weeks": 6,
                "genotoxic_metabolite": "glycidamide_2,3-epoxypropionamide_CYP2E1",
                "peripheral_neuropathy": True,
                "threshold": AA_THRESHOLD,
            },
        )
        result = resp.json()
        if result["score"] >= AA_THRESHOLD:
            raise AdversarialAcrylamideError(surface, result["score"], frame_hash)
        return result

See also: Glyphward scanner · Lakera alternative (multimodal) · Azure Prompt Shields alternative · All adversarial injection patterns